Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Cogent Biosciences (NASDAQ: COGT) slips after hours as insider sales prompt investor scrutiny
Cogent Biosciences stock fell after hours on insider sales by multiple executives. Find out why it matters now and what it means for investors going forward.
GSK dodges tariffs with a massive pricing pivot—but what’s the catch?
GlaxoSmithKline cuts drug prices in the U.S. and secures tariff relief under a new federal deal. Find out what this means for pharma's future pricing playbook.
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Lupin (NSE: LUPIN) signs licensing deal with Gan & Lee for Bofanglutide GLP-1 in India
Lupin signs exclusive India deal for Bofanglutide, a novel fortnightly GLP-1. Find out how it could reshape the obesity and diabetes market in 2026.
Sanofi bets $2.2bn on Dynavax to expand adult vaccine pipeline with hepatitis B and shingles focus
Find out how Sanofi’s $2.2B Dynavax buyout could reshape its adult vaccine strategy with HEPLISAV-B and a new shingles candidate in development.
Mabwell’s anti-ST2 antibody enters U.S. trials: Can 9MW1911 reshape immunotherapy for COPD?
Mabwell’s anti-ST2 antibody 9MW1911 enters U.S. trials after strong COPD data in China. Find out what this could mean for immunotherapy's future in COPD.
Biohaven (NYSE: BHVN) deprioritizes BHV-7000 in depression after Phase 2 miss, shifts focus to epilepsy, obesity, and immunology
Biohaven ends BHV-7000 depression trials after Phase 2 miss. Find out why it's shifting R&D focus to epilepsy, obesity, and immunology in 2026.
Glioblastoma trial for MT027 moves forward as T-MAXIMUM debuts allogeneic cell therapy in CNS
T-MAXIMUM wins FDA clearance for MT027 in glioblastoma. Read how its non-viral, off-the-shelf CAR-T may reshape solid tumor cell therapy development.
Will Pictor’s targeted proteomics platform gain traction after CDC’s hepatitis B shift?
Pictor’s ViraScreen-Core test aligns with new CDC hepatitis B guidance. Find out how this multiplex assay could reshape antibody testing in clinical labs.
Rubraca beats docetaxel in TRITON3: FDA clears early-line prostate cancer use for Tolmar
Tolmar’s Rubraca gains FDA approval for BRCA-mutated prostate cancer before chemotherapy. Explore the trial results and what it means for treatment strategy.